VALBY, Denmark, June 4, 2026
H. Lundbeck A/S has announced encouraging results from its Phase IIb PROCEED clinical trial evaluating bocunebart (Lu AG09222), an investigational anti-PACAP monoclonal antibody being developed for migraine prevention. Presented at the American Headache Society (AHS) Congress 2026 in Orlando, Florida, the findings demonstrated that bocunebart achieved the primary endpoint of the study, significantly reducing monthly migraine days in patients who had previously experienced failure with one to four preventive migraine therapies. The positive results strengthen the growing body of evidence supporting PACAP pathway inhibition as a novel mechanism for migraine prevention and position bocunebart as a potential breakthrough treatment option for patients who continue to experience substantial disease burden despite currently available therapies. The announcement marks an important milestone in Lundbeck’s expanding neuroscience pipeline and highlights continued innovation in the treatment of chronic neurological disorders.
Phase IIb PROCEED Trial Meets Primary Endpoint
The intravenous portion of the Phase IIb PROCEED dose-finding study successfully met its primary endpoint, demonstrating a statistically significant reduction in monthly migraine days compared with placebo during the 12-week treatment period. Patients receiving bocunebart achieved a mean reduction of 4.24 monthly migraine days, compared with a reduction of 2.86 days in the placebo group, resulting in a treatment difference of 1.38 fewer migraine days per month. Researchers reported statistically significant efficacy outcomes, reinforcing the therapeutic potential of targeting the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway.
Particularly noteworthy were the results observed among patients with severe chronic migraine who had experienced previous preventive treatment failures. In pooled analyses across the Phase II clinical development program, these patients demonstrated a mean reduction of 5.94 monthly migraine days, compared with 3.63 days for placebo, reflecting an even greater treatment benefit. These findings suggest that bocunebart may provide meaningful clinical improvements for individuals who remain inadequately controlled despite existing preventive treatment options.
Novel PACAP Mechanism Offers New Hope for Patients
Advertisement
Unlike currently marketed anti-CGRP therapies, bocunebart is designed to selectively bind and inhibit PACAP, a neuropeptide increasingly recognized as a key contributor to migraine pathophysiology. This differentiated mechanism offers a potentially important therapeutic alternative for patients who do not respond adequately to available migraine prevention treatments. Migraine remains one of the most disabling neurological diseases worldwide and is a leading cause of disability among people under the age of 50. Despite significant advances in migraine management, many patients continue to experience frequent attacks that negatively affect quality of life, productivity, and daily functioning.
By targeting a biological pathway distinct from CGRP, bocunebart could potentially expand treatment options and address unmet medical needs within the migraine community. Experts presenting the data highlighted the potential of PACAP inhibition to become an entirely new therapeutic class in migraine prevention, opening the door to innovative treatment strategies for millions of patients globally.
Favorable Safety Profile Supports Continued Development
In addition to its efficacy results, bocunebart demonstrated a favorable safety and tolerability profile throughout the Phase II program. Investigators reported that the therapy was generally well tolerated, with no new safety signals identified during treatment. The most commonly reported treatment-emergent adverse event was nasopharyngitis, while overall safety findings remained consistent with previous clinical observations. Lundbeck also presented Phase I data evaluating bocunebart in combination with commonly prescribed acute migraine therapies, including ubrogepant, further supporting the treatment’s compatibility within existing migraine management approaches.
The positive outcomes from both efficacy and safety evaluations have prompted Lundbeck to advance preparations for the next stages of clinical development. As the company continues to expand its neuroscience portfolio, bocunebart represents one of the most promising investigational candidates targeting a novel migraine pathway. The latest clinical results reinforce confidence in PACAP inhibition and underscore the potential of bocunebart to become a transformative preventive therapy for patients living with chronic and difficult-to-treat migraine.
Source: Lundbeck press release
